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Background/aim: The aims of this study were to evaluate measles incidence and the effect of elimination strategy interventions on the
disease from 1960 to 2014 in Turkey. The administration of measles vaccine started in the rural regions in 1970; it was carried out as
a campaign along with the National Vaccine Campaign in 1985, and it has been employed as combined measles, mumps, and rubella
under the scope of the Measles Elimination Program (MEP) since 2006 in Turkey. While a dramatic decrease in the reporting of measles
was observed between 2000 and 2010, the number of the cases has increased since 2011.
Materials and methods: The time series of measles incidence was evaluated for possible structural changes with regression models
using dummy variables, autocorrelated with error terms.
Results: The incidence of measles showed a statistically significant decline between 1985 and 1988 (P = 0.0072) and between 2005 and
2011 (P < 0.0001). However, a statistically significant increase in incidence was noted after 2013 (P = 0.0008).
Conclusion: Over the last 54 years, the pattern of measles cases demonstrated a significant decline in incidence. However, the increase
in incidence in 2013 should be carefully analyzed and interpreted in terms of the MEP.
Key words: Burden of measles, measles elimination, measles incidence, Turkey

1. Introduction
Measles is the third vaccine-preventable infectious disease
that the World Health Organization (WHO) aims to
eradicate after elimination (1–6). Due to its high morbidity
and mortality, measles is 1 of the 6 diseases that were
included in the 1974 Expanded Immunization Program
(EIP). Following elimination of the disease in the western
Pacific region in 2002, WHO now aims to eliminate measles
by 2020 in 5 more regions and the discussion on possible
measles eradication strategies has already begun (2,6,7–13).
WHO and combined measles, mumps, and rubella (MMR)
initiatives have amended the target elimination year from
2010 to 2015 because epidemics occurred between 2007 and
2013 in the European region where the elimination program
was being implemented (14–16). In 2010, WHO’s Strategic
Advisory Group of Experts on Immunization conducted a
comprehensive evidence review to establish the biological
and technical feasibility of measles eradication and
concluded that measles can and should be eradicated (17).
1.1. Measles in Turkey
As shown in Table 1, according to the Ministry of Health
data, a total of 66,111 cases of measles were reported in
Turkey in 1969 before vaccination when measles was a
* Correspondence: caliskan@medicine.ankara.edu.tr

nationally notifiable disease (18). Administration of the
measles vaccine was initiated in 1970, primarily in rural
regions (19).
Measles cases in Turkey and the elimination strategy
of the Ministry of Health (1960–2013) are presented in
Figure 1. The chronological history of fighting measles
in Turkey started with National EIP in 1981; EIP, as well
as a National Vaccine Campaign (NVC), was established
in 1985 (20). The Measles Vaccination Acceleration
Campaign was implemented in 1996, and a second-dose
measles vaccine was administered to first-grade children
in 1998. The Measles Elimination Program (MEP) has
been running since 2006 (21–23). The purpose of this
program was to eliminate measles in Turkey, maintain a
low level of infection, halt indigenous virus transmission
in Turkey by 2010, hinder the measles colonization due to
importation, and prevent deaths. After 2006, “the Measles
and Rubella Elimination and Prevention of Congenital
Rubella Syndrome Program” was initiated and the triple
MMR vaccine started.
The aim of this study was to evaluate measles incidence
and the effect of elimination strategy interventions on the
measles disease in 1960–2014 in Turkey.
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Table 1. The number of measles cases and measles incidence
between 1960 and 2014 in Turkey.
Years
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014**

Number of measles cases
15,926
16,604
10,347
18,517
17,312
52,617
50614
42,906
38,266
66,111
46,761
43,002
23,601
43,271
12,836
24,347
21,740
16,123
12,517
11,745
8618
26,547
8778
31,515
30,666
14,695
2267
2194
9279
19,273
11,372
22,521
24,626
34,285
23,733
13,544
27,171
22,795
27,120
16,329
16,010
30,509
7810
5600
8744
1119
34
3
4
4
7
111
349
7405
529

Measles incidence*
57.9
58.82
35.76
62.45
56.96
168.92
158.49
131.01
113.93
191.94
132.39
118.74
63.56
113.65
32.88
60.83
53.13
38.6
29.35
26.98
19.39
58.29
18.8
65.84
62.49
29.21
4.4
4.19
17.42
35.56
20.63
40.18
43.21
59.2
40.34
22.67
44.78
37.02
43.42
25,77
24.91
46.84
11.83
8.37
12.91
1.63
0.05
0
0.01
0.01
0.01
0.15
0.46
9,68
0,65

*Incidence is defined as the number of cases per 100,000 individuals.
**Cases were only diagnosed in the first 9 months.
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2. Materials and methods
The incidence of measles was calculated according to
the number of reported measles cases and compared
with population census data for each respective year. To
satisfy the assumptions of the present model, the natural
logarithm of the series was determined (24,25). The Box–
Cox transformation for time series variables was applied to
determine the need for stabilizing variance and satisfying
the normality assumption. After the application of Box–
Cox, the natural logarithm of the series was taken (25).
To analyze the significance of special events that might
affect measles incidence, the transformed series was
regressed with the intercept and some indicator functions
for certain time periods. Using the history of measles
incidence the following dummy variables were chosen:
I1 = *

1, if 1964 < Year < 1974
0, otherwise

I2 = *

1, if 1973 < Year < 1975
0, otherwise

I3 = *

1, if 1981 < Year < 1985
0, otherwise

I4 = *

1, if 2005 < Year < 2011
0, otherwise

I5 = *

1, if 2013 # Year # 2014
0, otherwise

I6 = *

1, if 1985 < Year < 1988
0, otherwise

I7 = *

1, if 1995 < Year < 1999
0, otherwise

I8 = *

1, if 2001 < Year < 2011
0, otherwise

To take into account problems due to autocorrelated
errors, regression with dummy variables and autoregressive
error models—specifically AR (1)—was performed
(Figure 2).
All model diagnostics were satisfied. Parameter
estimates of the models are given in Table 2. Variables
I1–I8 presented the dummy variables. The firstorder autoregression estimate was determined for the
autocorrelated error model. Because variables I1–I3,
I7, and I8 were not statistically significant at 5%, these
variables were eliminated and the model was refitted.
The probabilities provided in the last column of the
table indicate that all model parameters are statistically
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Figure 1. Measles cases in Turkey and elimination strategy (1960–2013).
Table 2. Parameter estimates of the regression with AR (1) error model.
Variable (years)

DF

Estimate

Standard error

t Value

Significance

I4 (2005–2011)

1

−3.1589

0.5917

−5.34

<0.0001

I5 (2013–2014)

1

2.9601

0.8265

3.58

0.0008

I6 (1985–1988)

1

−1.6567

0.5915

−2.80

0.0072

AR (1) Autoregressive model (1)

1

−0.9756

0.0261

−37.39

<0.0001

significant at 5% and should be included. Dummy
variables I4–I5 decreased the incidence of measles,
whereas I6 increased the incidence. Because logarithmic
transformation was applied to the series before analysis,
the exponent of the estimates was used to conclude the
actual measles incidence. The coefficient of determination
of the model was 95.49%, which indicated a very high
variation in measles incidence and explained the variation
in the given dummy variables.
SAS/ETS 9.2 (2008) software (SAS Institute Inc., NC,
USA) was used to perform all statistical analyses. Figure
2 shows the close fit of the original and predicted values.

i.e. after the 1985 NVC was implemented, and 2005–2011
(P < 0.0001), i.e. after the 2002 MEP and 2006 MMR
vaccination were implemented (as seen in Table 2). The
measles incidence decreased by 3.1589 units (incidence),
on average, between 2005 and 2011 and between 1985
and 1988 with the presence of the fourth dummy variable;
the presence of the fifth dummy variable resulted in a
decrease of 1.6567 units (incidence), on average. However,
in 2013 and during the first 9 months of 2014 (7405 and
529 cases), the log value of measles incidence increased
to preelimination levels, i.e. 2.9601 units (incidence) on
average (P = 0.0008).

3. Results
When the 1960–2014 measles incidence in Turkey
was analyzed using regression modeling, statistically
significant drops were observed in 1985–1988 (P ≤ 0.0072),

4. Discussion
The aim of this study was to evaluate measles incidence
since 1960 in Turkey. The Ministry of Health (MoH) in
Turkey started measles vaccination in 1970 and the MEP
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Figure 2. Time series plot of 54 years of measles incidence rates in Turkey and predicted values obtained
using AR (1) regression error modeling.

in 2002. To show the significance of these interventions, a
regression model was used. When the 1960–2014 measles
incidence in Turkey was analyzed, 3 critical periods were
detected (as shown in Figures 1 and 2).
A first drop period (1985–1988) followed the 1985
NVC. However, measles vaccination rates remained
rather low prior to the 1981 EIP (25%–35%). A NVC
was established in 1985, and 92% of the children <5
years of age were vaccinated at the end of this campaign
(20). Following implementation of the NVC, the number
of reported cases dropped from 2267 to 2194 in 2 years
(1986–1987), as shown in Table 1.
A second drop period (2005–2011) followed the 2002
MEP and the onset of MMR vaccination program in 2006.
The Measles Vaccination Acceleration Campaign was
implemented in 1996, and a second-dose measles vaccine
was administered to first-grade children in 1998. As shown
in Table 1, in 2001, 30,509 measles cases were reported. The
MEP has been running since 2002 (21–23). Accordingly,
the 2003–2005 MEP implemented measles vaccination
days, to administer catch-up vaccinations to individuals
in sensitive cohorts (this initiative was separate from
keep-up and follow-up activities). This program has been
conducted as part of the Measles and Rubella Elimination
and Prevention of Congenital Rubella Syndrome Program
since 2006 and, accordingly, the MMR vaccine has been
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administered. All children attending elementary school
were vaccinated during 2006–2008. Furthermore, a catchup study was performed with individuals between 18
and 35 years of age in 33 provinces in 2009. The circular
published by the MoH in 2010 reported the province-wide
requirements for achieving measles surveillance, detecting
potential epidemics, and effectively responding to and
controlling epidemics in Turkey. In total, 18,216,897
children between 9 months and 14 years of age were
vaccinated as part of the 2002 MEP, thereby achieving a
vaccination rate of 96%. A dramatic drop in the number
of measles cases was achieved, and no indigenous cases
were reported in 2008–2010 (23). The decreased trend
continued through 2012 with 349 cases (Table 1).
During the third period, the number of cases increased
incrementally after 2013. As shown in Table 1, 7405
measles cases were reported in 2013. The MoH reported
that this increase was not defined as an epidemic but
instead described as a controlled increase in 2013, and all
cases were classified as imported or related to an imported
case (26,27,28). Unlike the MoH, in a report published
by the Public Health Specialist Society in March 2013,
the increase in measles was considered as an epidemic
and, because of a large influx of refugees since 2013, this
period was evaluated carefully (29). The official number
of Syrian refugees in Turkey was 1,805,255, but the
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estimated number was around 2,500,000 (30). According
to the report of “Disaster and Emergency Management
Presidency” (DEMP), 28.2% of children aged less than
10 years in the camps and about 41.3% of children out
of the camps were not vaccinated against measles. This
posed a serious health threat for children among the local
population (31). Moreover, the MoH reported that the
importation risk increased because of Syrian refugees’ low
vaccination rates (28).
The WHO defines a measles epidemic according to
the national vaccination program. A higher number of
cases than expected can still be defined as an epidemic if
the vaccination rates are low; however, in countries where
elimination programs are implemented, an incidence
that exceeds 1 case per 100,000 people is considered an
epidemic (32). According to this criterion, the measles
incidence of 2013 Turkey reflects an epidemic. Because
of the high virulence and infection rate of the measles
virus, epidemics can be observed in vaccinated and
nonvaccinated groups in regions where elimination
programs halt indigenous transmission (5,6,13,16,32–34).
The MoH reported that a significant portion of measles
cases in 2013 included infants who had not yet been
vaccinated. Therefore, the Measles Science Committee
(MSC) recommended that first-dose MMR vaccination
should be administered at 9 months instead of 12 months
and second-dose vaccine should be administered at 12
months. The MSC also recommended that first-grade
children should be vaccinated during nursery school,
and military personnel, relatives of new patients, and
disadvantaged and other low-socioeconomic groups
should also be vaccinated by mobile health teams.
Accordingly, approximately 4,000,000 people were
vaccinated in 2013 (28,29). The increase in the number
of cases was controlled using these precautions, and only
529 cases were detected by the end of September 2014.
After the present analysis, the MoH announced that only
5 cases were added in the last 3 months in 2014. Statistical
analysis was not repeated due to the small number of

added measles cases. Considering the 2014 cases, it can
be said that the MoH succeeded in these interventions in
2013 (28). The course of measles reveals that interventions
could effectively reduce the incidence in Turkey. The 2013
increase in incidence needs to be carefully interpreted by
program administrators. The MoH reported that 2013
cases were imported cases and their precautions were
effective. Since 2005, epidemics reported in the European
region (35–39), and the last epidemic experienced in
Turkey, showed that it is impossible to eradication measles
now (11,13,29,34,40). Particular factors including high
infectivity, virulence, pathogenicity, inadequate cold chain,
unsafe administration, groups who refuse vaccination
or cannot be reached, incomplete protective properties
of the vaccine, waning immunity, gradual increase in
the sensitive pool over subsequent years, immigration,
international travel, and so forth were the biggest barriers
to eradication (11,13,29,34,40).
Over the last 54 years, the pattern in measles cases
demonstrated that the incidence could be lowered
effectively. However, the increase in incidence during 2013
should be carefully analyzed and interpreted in terms of
the MEP. For diseases such as measles with high infection
rates, it is important to reach 95% and more immunity
in the populations. Therefore, the immunity levels of
refugee children should be monitored carefully. Only the
kindergarten children who were enrolled in the Ministry
of National Education Schools were vaccinated during the
2013 outbreak. The effects of the Health Transformation
Program (started in 2003), especially the primary care
services, have to be considered. The performance of the
contracting scheme (the immunization coverage rate of
registered children) might affect the access of unregistered
children to preventive services. Social awareness related to
measles epidemic was relatively low in Turkey. Awareness
among the community, motivation of health professionals
for better coverage of preventive services, and motivation
of people for utilization of preventive services are some
necessary steps for the management of cases.

References
5.

Keegan R, Dabbagh A, Strebel PM, Cochi SL. Comparing
measles with previous eradication programs: enabling and
constraining factors. JID 2011; Supp l1: 54-61.

WHO Regional Office for Europe .Eliminating measles and
rubella framework for the verification process in the WHO
European Region http://www.euro.who.int/__data/assets/pdf_
file/0005/156776/e96153-Eng-final-version.pdf.

6.

3.

Measles & Rubella Initiative: The Problem. http://www.
measlesrubellainitiative.org/learn/the-problem/.

WHO. Global eradication of measles, report by the secretariat,
Sixty-Third World Health Assembly, A63/18. http://apps.who.
int/gb/ebwha/pdf_files/WHA63/A63_18-en.pdf.

7.

Cutts FT, Henao-Restrepo AM, Olive JM. Measles elimination:
progress and challenges. Vaccine 1999; 17: 47-52.

4.

Measles & Rubella Initiative Annual Report 2012. http://www.
measlesrubellainitiative.org/wp-content/uploads/2013/07/
MRI-2012-Annual-Report.pdf.

8.

Kelly H, Riddell M, Heywood A, Lambert S. WHO criteria for
measles elimination: a critique with reference to criteria for
polio elimination. Euro Surveill 2009; 14: pii=19445.

1.

Hinman AR, Orenstein WA, Schuchat A. Vaccine-preventable
diseases, immunizations, and MMWR 1961–2011. MMWR
Surveill Summ 2011; Supp 60: 49-57.

2.

1105

ÇALIŞKAN et al. / Turk J Med Sci
9.

Martínez A, Torner N, Domínguez A, Barrabeig I, Rovira
A, Rius C, Caylà JA, Plasencia E , Minguell S, Parrón I et al.
Measles outbreak in the elimination era. The Open Vaccine
Journal 2010; 3: 42-47.

26.

The Ministry of Health of Turkey Public Health Agency of
Turkey. Response to written question No. 21001706 dated
12.09.2013 (in Turkish) http://www2.tbmm.gov.tr/d24/7/722609sgc.pdf.

10.

Centers for Disease Control and Prevention. Global control
and regional elimination of measles, 2000–2011. MMWR
Morb Mortal Wkly Rep 2013; 62: 27-31.

27.

The Ministry of Health of Turkey Public Health Agency of
Turkey. Measles subject press release dated 23.11.2013 (in
Turkish).

11.

Orenstein WA, Strebe PM, Papani, M. Measles eradication: is it
in our future. Am J Public Health 2000; 90: 1521-1525.

28.

12.

Quadros CA, Andrus JK, Danovaro-Holliday MC, CastilloSolórzano C. Feasibility of global measles eradication after
interruption of transmission in the Americas. Expert Review
of Vaccines 2008; 7:3,355-362.

The Ministry of Health of Turkey. Measles knowledge of notes
for physician 2015 (in Turkish) http://www.duzcehalksagligi.
gov.tr/index.php/duyurular-menu-top/220-k-zam-k-bilginotu.

29.

Public Health Specialist Association Communicable Diseases
Working Group (2013) Measles report (in Turkish) http://
hasuder.org.tr/anasayfa/jupgrade/images/HASUDER_
KIZAMIK_RAPORU.pdf.

30.

Republic of Turkey Prime Ministry Disaster and Emergency
Management Presidency. Syrian Refugees in Turkey, 2013
https://www.afad.gov.tr/Dokuman/TR/61-2013123015505syrian-refugees-in-turkey-2013_print_12.11.2013_eng.pdf.

31.

The
UN
Refugee
pages/49e48e0fa7f.html.

32.

WHO. Response to measles outbreaks in measles mortality
reduction settings. http://whqlibdoc.who.int/hq/2009/who_
ivb_09.03_eng.pdf.

33.

WHO Regional Office for Europe. Surveillance guidelines for
measles, rubella and congenital rubella syndrome in the WHO
European Region update December 2012.

34.

WHO European Region. Surveillance guidelines for measles,
rubella and congenital rubella syndrome in the WHO European
Region http://www.ncbi.nlm.nih.gov/books/NBK143264/pdf/
TOC.pdf.

35.

Delaporte E, Wyler Lazarevic CA, Iten A, Sudre P. Large measles
outbreak in Geneva, Switzerland, January to August 2011:
descriptive epidemiology and demonstration of quarantine
effectiveness. Euro Surveill 2013; 8: pii=20395.

36.

Delgado de los Reyes JA, Arencibia Jimenez M, Navarro Gracia
JF, Alonso Echabe E, Garcia Puente P, Banqueri Guerrero
EM, Pérez Torregrosa G , Calle Barreto JD, Zurriaga Carda
R. Ongoing measles outbreak in Elche, Spain, 29 January to 9
March 2012. Euro Surveill 2012; 17: pii=20119.

37.

Vivancos R, Keenan A, Farmer S, Atkinson J, Coffey E,
Dardamissis E, Dillon J, Drew RJ, Fallon M, Huyton R et al.
An ongoing large outbreak of measles in Merseyside, England,
January to June 2012. Euro Surveill 2012; 17: pii=20226.

38.

Antona D, Lévy-Bruhl D, Baudon C, Freymuth F, Lamy M,
Maine C, Floret D, Parent du Chatelet I. Measles elimination
efforts and 2008-2011 outbreak, France. Emerg Infect Dis
2013; 19: 357-364.

39.

Centers for Disease Control and Prevention. Increased
transmission and outbreaks of measles, European Region,
2011. MMWR Morb Mortal Wkly Rep 2011 http://www.cdc.
gov/mmwr/pdf/wk/mm6047.pdf.

40.

Bandyopadhyay AS., Utpala Bandy U. Emerging global
epidemiology of measles and public health response to
confirmed case in Rhode Island. Rhode Island Medical Journal
2013; 96: 41-44.

13.

WHO. Global measles and rubella strategic plan: 2012-2020.
http://whqlibdoc.who.int/publications/2012/9789241503396_
eng.pdf.

14.

Henao-Restrepo AM, Strebel P, Hoekstra EJ, Birmingham M,
Bilous J. Experience in Global Measles Control, 1990–2001,
JID 2003; Supp 11: 15-21.

15.

Simons E, Ferrari M, Fricks J, Wannemuehler K, Anand A,
Burton A, Strebel P. Assessment of the 2010 global measles
mortality reduction goal: results from a model of surveillance
data. Lancet 2012; 379: 2173-2178.

16.

17.

18.

WHO Regional Office for Europe. WHO EpiBrief A report on
the epidemiology of selected vaccine-preventable diseases in
the European Region 2013; No:2.
SAGE Working group on measles and rubella. Status report on
progress towards measles and rubella elimination http://www.
who.int/immunization/sage/meetings/2012/november/1_
Status_Report_Measles_Rubella_22_Oct.pdf.
The Ministry of Health of Turkey Headquarters of Contagious
and Epidemic Diseases Control Departments with VaccinePreventable Diseases. Measles elimination program
presentation 2014 (in Turkish) www.kayseri.hsm.saglik.gov.tr/
images/dosyalar/20140610081729_3.pptx.

19.

The Ministry of Health of Turkey General Directory of
Primary Health Services Headquarters of Contagious and
Epidemic Diseases Control. Measles Elimination Program,
Measles field guide (in Turkish). http://www.mersinsaglik.gov.
tr/Download%5C231_10_kizamik_saha_rehberi.pdf.

20.

Buzgan T. History of vaccination policies, in Turkey. J Pediatr
Inf 2011; Suppl 1: 235-238 (in Turkish).

21.

Ceyhan M. Measles vaccination in Turkey. (in Turkish) Çocuk
Sağlığı ve Hastalıkları Dergisi 2005; 48: 206-208. http://cshd.
org.tr/csh/pdf/pdf_CSH_152.pdf.

22.

Kurugöl Z. Measles in Turkey: a continuing problem. Türkiye
Klinikleri J Pediatr 2006; 15: 52-58 (article in Turkish with an
abstract in English).

23.

The Ministry of Health of Turkey General Directory of Primary
Health Services. Measles rubella and congenital rubella
syndrome surveillance circular. (in Turkish) http://www.
saglik.gov.tr/HM/dosya/1-62449/h/kizamik-kizamikcikkkssurveyansigenelgesi2010.pdf.

24.

Pankratz A. Forecasting with univariate Box-Jenkins Models:
concepts and cases. New York, NY, USA: John Wiley; 1983.

25.

Taylor JMG. The retransformed mean after a fitted power
transformation. Journal of the American Statistical Association
1986; 81: 114-118.

1106

Agency.

http://www.unhcr.org/

